| __timestamp | Iovance Biotherapeutics, Inc. | Taro Pharmaceutical Industries Ltd. |
|---|---|---|
| Wednesday, January 1, 2014 | 9335772 | 91733000 |
| Thursday, January 1, 2015 | 12390000 | 87644000 |
| Friday, January 1, 2016 | 25602000 | 92365000 |
| Sunday, January 1, 2017 | 21262000 | 85656000 |
| Monday, January 1, 2018 | 28430000 | 88196000 |
| Tuesday, January 1, 2019 | 40849000 | 89971000 |
| Wednesday, January 1, 2020 | 60210000 | 93413000 |
| Friday, January 1, 2021 | 83664000 | 91355000 |
| Saturday, January 1, 2022 | 104097000 | 113676000 |
| Sunday, January 1, 2023 | 106916000 | 198366000 |
| Monday, January 1, 2024 | 218935000 |
Igniting the spark of knowledge
In the competitive world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Iovance Biotherapeutics, Inc. and Taro Pharmaceutical Industries Ltd. have taken different paths in this regard over the past decade.
From 2014 to 2023, Taro consistently maintained higher SG&A expenses, peaking at nearly $219 million in 2023. This represents a 150% increase from their 2014 expenses. In contrast, Iovance's SG&A costs grew more dramatically, surging over 1,000% from 2014 to 2023, reaching approximately $107 million.
While Taro's expenses show a steady upward trend, Iovance's rapid increase suggests aggressive expansion or investment in administrative capabilities. The data for 2024 is incomplete, but Taro's continued rise hints at further strategic investments. Understanding these trends can offer insights into each company's operational strategies and market positioning.
Cost Management Insights: SG&A Expenses for argenx SE and Iovance Biotherapeutics, Inc.
Cost Management Insights: SG&A Expenses for Madrigal Pharmaceuticals, Inc. and Iovance Biotherapeutics, Inc.
Who Optimizes SG&A Costs Better? Grifols, S.A. or Iovance Biotherapeutics, Inc.
Verona Pharma plc vs Iovance Biotherapeutics, Inc.: SG&A Expense Trends
CRISPR Therapeutics AG or Taro Pharmaceutical Industries Ltd.: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of Rhythm Pharmaceuticals, Inc. and Iovance Biotherapeutics, Inc.
Comparing SG&A Expenses: PTC Therapeutics, Inc. vs Taro Pharmaceutical Industries Ltd. Trends and Insights
Who Optimizes SG&A Costs Better? MorphoSys AG or Taro Pharmaceutical Industries Ltd.
Bausch Health Companies Inc. vs Iovance Biotherapeutics, Inc.: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing Amicus Therapeutics, Inc. and Iovance Biotherapeutics, Inc.
Vericel Corporation vs Taro Pharmaceutical Industries Ltd.: SG&A Expense Trends
Mesoblast Limited vs Taro Pharmaceutical Industries Ltd.: SG&A Expense Trends